Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes - Trial NCT06416995
Access comprehensive clinical trial information for NCT06416995 through Pure Global AI's free database. This phase not specified trial is sponsored by Umraniye Education and Research Hospital and is currently Recruiting. The study focuses on Preeclampsia,Gestational Hypertension,Gestational Diabetes,Preterm Birth,Fetal Growth Retardation. Target enrollment is 88 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
first trimester serum diagnostic test
Observational
diagnostic test
Sponsor & Location
Umraniye Education and Research Hospital
Timeline & Enrollment
N/A
Mar 03, 2023
Dec 30, 2024
Primary Outcome
Usability of serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations in predicting adverse perinatal outcomes
Summary
Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2,
 cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and
 adverse perinatal outcomes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06416995
Non-Device Trial